The study of Parkinson’s disease main etiological factors

Authors

DOI:

https://doi.org/10.15587/2519-4852.2017.103780

Keywords:

Parkinson's disease, etiological factors, average cost, prevalence, international experience

Abstract

Parkinson’s disease is the 2nd most common neurodegenerative disease among elderly people. Nowadays, in Europe there are more then 1.2 million people injured with this disease and their number is growing steadily.

Aim. The study of main etiological factors which determine the origin of Parkinson’s disease and its prevalence, as well as determination of the average costs level for Parkinson's disease treatment.

Methods. Content analysis, analytical and statistical methods of analysis.

Results. Etiological factors influencing on Parkinson's disease development, such as heredity, environmental impact, pesticides, bacterial and viral infections, as well as industrial toxic substances, were determined. Among the surveyed countries, the largest number of patients with Parkinson's disease was found in the United States and Hungary, while the largest average cost - in the UK and the US.

Conclusion. In general, the indexes of the number of patients and average costs among surveyed countries are quite unequal and require further research

Author Biographies

Alla Kotvitska, National University of Pharmacy Pushkinska str., 53, Kharkiv, Ukraine, 61002

Doctor of Pharmacy, Professor, Vice-rector for research and educational activities

Oleksii Prokopenko, National University of Pharmacy Pushkinska str., 53, Kharkiv, Ukraine, 61002

Postgraduate Student

Department of Social Pharmacy

References

  1. Obeso, J. A., Rodriguez-Oroz, M. C., Goetz, C. G., Marin, C., Kordower, J. H., Rodriguez, M. (2010). Missing pieces in the Parkinsons disease puzzle. Nature Medicine, 16 (6), 653–661. doi: 10.1038/nm.2165
  2. Warner, T. T., Schapira, A. H. (2003). Genetic and environmental factors in the cause of Parkinson’s disease. Annals of Neurology, 53 (3), 16–23. doi: 10.1002/ana.10487
  3. Kowal, S. L., Dall, T. M., Chakrabarti, R., Storm, M. V., Jain, A. (2013). The current and projected economic burden of Parkinsons disease in the United States. Movement Disorders, 28 (3), 311–318. doi: 10.1002/mds.25292
  4. von Campenhausen, S., Winter, Y., Silva, A. R., Sampaio, C., Ruzicka, E., Barone, P. et. al. (2011). Costs of illness and care in Parkinson's Disease: An evaluation in six countries. European Neuropsychopharmacology, 21 (2), 180–191. doi: 10.1016/j.euroneuro.2010.08.002
  5. Kotvitska, A., Prokopenko, O. (2017). Doslidzhennia ekonomichnoi skladovoi problemy khvoroby Parkinsona u riznykh krainakh svitu [Research of economic burden of Parkinson’s disease in various countries]. Aktual'ni problemy rozvytku haluzevoyi ekonomiky ta lohistyky. Kharkiv, 400–403.
  6. Schapira, A. H., Jenner, P. (2011). Etiology and pathogenesis of Parkinson's disease. Movement Disorders, 26 (6), 1049–1055. doi: 10.1002/mds.23732
  7. Evtushenko, S., Holovchenko, Y., Trufanov, E. (2014). Bolezn Parkynsona y parkynsonycheskye syndromi (lektsyia) [Parkinson’s disease and it’s syndromes (lecture)]. International neurourology journal, 4. Available at: http://www.mif-ua.com/archive/article/38950
  8. National Parkinson’s foundation. The Stages of Parkinson’s Disease. Available at: http://www.parkinson.org/understanding-parkinsons/what-is-parkinsons/The-Stages-of-Parkinsons-Disease
  9. Valldeoriola, F.; Finkelstein, D. (Ed.) (2011). Cost and Efficacy of Therapies for Advanced Parkinsons Disease. Towards New Therapies for Parkinsons Disease. doi: 10.5772/17862
  10. Public Health Agency of Canada. Available at: http://www.phac-aspc.gc.ca/index-eng.php
  11. The European Parkinson’s Disease standards of care consensus (2012). EPDA, 2.
  12. Dodel, R. (2008). The Economic Burden of Parkinson’s Disease. European Neurological Review, 3 (2), 11–14.
  13. Linder, J., Stenlund, H., Forsgren, L. (2010). Incidence of Parkinson's disease and parkinsonism in northern Sweden: a population-based study. Movement Disorders, 25 (3), 341–348. doi: 10.1002/mds.22987
  14. Mateus, C., Coloma, J. (2012). Health Economics and Cost of Illness in Parkinsons Disease. European Neurological Review, 8 (1), 6–9. doi: 10.17925/enr.2013.08.01.6
  15. Tamas, G., Gulacsi, L., Bereczki, D., Baji, P., Takats, A., Brodszky, V., Pentek, M. (2014). Quality of Life and Costs in Parkinsons Disease: A Cross Sectional Study in Hungary. PLoS ONE, 9 (9), 1–7. doi: 10.1371/journal.pone.0107704
  16. Neurological disorders: public health challenges (2006). World Health Organization, 232.

Downloads

Published

2017-06-27

How to Cite

Kotvitska, A., & Prokopenko, O. (2017). The study of Parkinson’s disease main etiological factors. ScienceRise: Pharmaceutical Science, (3 (7), 15–18. https://doi.org/10.15587/2519-4852.2017.103780

Issue

No. 3 (7) (2017)

Section

Pharmaceutical Science

License

Copyright (c) 2017 Alla Kotvitska, Oleksii Prokopenko

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.